Roche's KRAS inhibitor divarasib shows positive lung cancer data at ESMO
Source Summary
Roche presented clinical trial data for divarasib, a KRAS-targeting drug for lung cancer treatment, at the European Society for Medical Oncology (ESMO) conference. The study results were described as one of the more impressive data sets presented at the conference.
Why it matters
Positive clinical data for a KRAS-targeted lung cancer therapy represents a significant advance in treating a previously difficult-to-target cancer mutation.
